–Treatment with HU6 led to significant reductions in body fat and abdominal visceral fat while preserving skeletal muscle in patients with obesity-related heart failure with preserved ejection ...
– New data from the HuMAIN study, which met the primary endpoint of weight loss and several efficacy and pharmacodynamic secondary endpoints, will be presented in a Late Breaking Clinical Research ...
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at ...
HU6, an oral, once-daily, potentially first-in-class investigational treatment, is a Controlled Metabolic Accelerator (CMA), which is designed to promote sustained body fat loss while preserving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback